Results 201 to 210 of about 673,473 (339)

Framing Modern Slavery: Do Stakeholders Talk Past Each Other?

open access: yesCanadian Journal of Administrative Sciences / Revue Canadienne des Sciences de l'Administration, EarlyView.
ABSTRACT Modern slavery literature has thus far mostly adopted a downstream perspective, in the sense that researchers investigated corporate actors' responses after the enactment of transparency legislation. The common finding is that corporate disclosure is poor and ineffective, contributing to a failure to eradicate modern slavery.
Sylvain Durocher   +2 more
wiley   +1 more source

Real‐World Edoxaban Concentrations in Older Patients Receiving Reduced‐Dose Regimens

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Real‐world edoxaban concentrations in older patients receiving reduced‐dose regimens. Low trough concentrations (< 12 ng/mL) were associated with an increased risk of thromboembolism. Among patients meeting the ELDERCARE‐AF criteria, low drug levels were more frequent with the 15 mg regimen than with the 30 mg regimen.
Sung‐Chun Tang   +8 more
wiley   +1 more source

Capability Development in the European Medicines Regulatory Network—A European Learning Needs Analysis and Survey Study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The European Medicines Regulatory Network plays a critical role in safeguarding public health through the assessment and supervision of human medicines. However, rapid scientific and technological advancements have exposed capability deficits across the network, threatening timely and effective regulatory decision‐making.
Naomi Beard   +4 more
wiley   +1 more source

Quantification of Age and Sex Ratio Differences between Trial and Target Population for New Drugs

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Clinical trials are essential to understand the benefit‐harm profile of new drugs. Lack of adequate representation in age and sex ratio in clinical trials can result, for example, in higher side effects for underrepresented patients. We quantified differences in age and sex ratios between trial and target populations of new drugs approved by the FDA ...
Miquel Serra‐Burriel   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy